Skip to Content
 
 
 
 

D18-11141: Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Ventoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage

Objective

Clinical Trial Details »

Principal Investigator(s)
Roberto Ferro, MD

Clinical Trial Categories

  • Leukemia
Contact
Hematology Research Coordinators at 605-322-3090
or hematologyresearch@avera.org

Location

  • Avera Cancer Institute at Sioux Falls
    1000 E. 23rd Street
    Sioux Falls, SD 57105
    Main: 605-322-3000
    Alternate: 800-657-4377

Moving Health Forward

Avera is a health ministry rooted in the Gospel. Our mission is to make a positive impact in the lives and health of persons and communities by providing quality services guided by Christian values.

© 2022 Avera Health, Sioux Falls, SD. All Rights Reserved.